NervGen Pharma Corp. Prices $60M Public Offering of Shares and Warrants

Why It Matters

The infusion of $60 million gives NervGen the runway to accelerate clinical trials for its lead spinal‑cord injury therapy, potentially reshaping a market with high unmet demand. Successful development could also boost investor confidence and attract strategic partnerships or acquisition interest.

Key Takeaways

• NervGen priced 24M shares at $2.50 each, raising $60M
• Warrants exercisable at $3.68, expire in five years
• Proceeds will fund NVG‑291 clinical trials and working capital
• Fast‑Track and Orphan designations support NVG‑291 regulatory pathway
• Leerink and TD Cowen act as joint book‑runners

Pulse Analysis

NervGen Pharma Corp. announced the pricing of a $60 million underwritten public offering, consisting of 24 million common shares and an equal number of warrants. Each share and accompanying warrant sold for $2.50, while the warrants carry a $3.68 exercise price and a five‑year term. The transaction, managed by Leerink Partners and TD Cowen, is slated to close on May 26, 2026 and will be offered across Canada, excluding Quebec. The proceeds, less underwriting costs, will augment the company’s cash balance and fund upcoming milestones.

The capital is earmarked primarily for NVG‑291, NervGen’s lead neuroreparative peptide targeting the CSPG‑PTPσ pathway in spinal cord injury. NVG‑291 already holds Fast‑Track status from the FDA and Orphan Drug designation from the EMA, positioning it for an accelerated regulatory review. With an estimated $2 billion annual spend on spinal cord injury care in the United States, a successful therapy could capture a sizable share of a high‑unmet‑need market. Funding will support Phase 2/3 trial enrollment, data collection, and potential expansion into related neurologic indications.

For investors, the offering underscores confidence in NervGen’s pipeline and its ability to raise non‑dilutive capital despite a competitive biotech fundraising climate. The inclusion of immediately exercisable warrants provides upside potential if the share price appreciates post‑trial readouts. Should NVG‑291 demonstrate efficacy, the company could become a strategic acquisition target for larger pharmaceutical firms seeking to enter the neuro‑repair space. The deal also highlights the growing collaboration between Canadian and U.S. securities regulators, facilitating cross‑border capital flows for emerging biotech innovators.

Deal Summary

NervGen Pharma Corp. announced the pricing of an underwritten public offering of 24 million common shares and up to 24 million warrants at $2.50 per share, targeting gross proceeds of about $60 million. Joint book‑running managers Leerink Partners and TD Cowen will lead the offering, which is expected to close on May 26 2026. Proceeds will fund the development of NVG‑291 and general corporate purposes.